Release Date: Tuesday, October 13, 2020
Expiration Date: Wednesday, October 13, 2021

Educational Needs

Multidrug-resistant (MDR) Gram-negative bacteria are associated with substantial clinical and economic burden and continue to challenge clinicians in the acute care setting. For serious bacterial infections, such as hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), initial appropriate antimicrobial therapy is essential for favorable patient outcomes. Fortunately, several new and novel antimicrobials have been approved for the treatment of HABP/VABP that offer clinicians viable options to manage critically ill patients in a pathogen-specific manner. Optimized use of these agents requires a thorough understanding of their pharmacotherapeutic potential to fully realize their role in the clinical setting. This activity provides a detailed overview of new and novel antimicrobials approved for the treatment of HABP/VABP to empower clinicians to make informed decisions on the use of these agents when treating MDR Gram-negative infections.

Learning Objectives

At the conclusion of the educational activity, the learner should be able to:

  • Describe the pharmacological differences and similarities among newer antimicrobial agents used in the treatment of hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)
  • Discuss how the profiles of newer antimicrobials can help direct the selection of an optimal agent for HABP/VABP caused by multidrug-resistant Gram-negative bacteria

Target Audience:

This continuing medical education activity is planned to meet the needs of ID healthcare providers, including physicians, pharmacists, and microbiologists, in a variety of practice settings, including large and small health systems, outpatient clinics, managed-care organizations, long-term care facilities, and academia.



Keith A. Rodvold, PharmD, FCCP, FIDSA

UIC Distinguished Professor
Co-Director, Section of Infectious Diseases Pharmacotherapy
Colleges of Pharmacy and Medicine
University of Illinois at Chicago
Chicago, IL


Educational Format

As part of the overall educational initiative, this pre-activity webinar provides a detailed overview of new and novel antimicrobials approved for the treatment of HABP/VABP that target MDR Gram-negative pathogens. In preparation for the live IDWeek symposium, we encourage you to view this pre-activity webinar to broaden the understanding of key aspects of each of these agents, including spectrum of activity, pharmacokinetic/pharmacodynamic profile, and early efficacy and safety results. The live IDWeek symposium will build on this knowledge and discuss the clinical application of these agents when managing patients with HABP/VABP. The pre-activity webinar includes the following sections:

Overview of the clinical and safety profiles of:
  • Ceftazidime-avibactam
  • Ceftolozane-tazobactam
  • Imipenem-relebactam
  • Cefiderocol
Short discussion on:
  • Microbiological activity against problematic pathogens
  • Dosing for HABP/VABP
  • Efficacy from clinical trials
  • Safety issues/concerns




AccreditationThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

Nurse Practitioners
Nurse Practitioners will receive certificate of AMA PRA Category 1 Credit™ as this is an ACCME accredited program and its accreditation is recognized by Nurse Practitioner boards.

AccreditationCenter for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.0 contact hour (0.1 CEU) of continuing pharmacy education credits for participating in this activity.

ACPE UAN: 0473-9999-20-007-H01-P

Activity type: Knowledge-based

For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CME/CPE information including target audience, learning objectives, and disclosures.
  2. Review the activity in its entirety.
  3. Complete the Online Post Test, Evaluation, and Credit Application form
  1. Please note that to receive credit you must achieve a score of at least 75%.
  2. Pharmacists: The information that you participated will be uploaded to CPEMonitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit
  3. Physicians: Certificate of Credit will be emailed to you within 4 weeks.


Disclosure of Conflicts of Interest

In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.



Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.

Keith Rodvold, PharmD has relevant financial relationships with the following commercial interests:

  • Advisory Board: Entasis Therapeutics, Shionogi Inc., Qpex Biopharma
  • Consultant: BLC USA LP, Chimerix Inc., Debiopharm International, Janssen Pharmaceuticals, Qpex Biopharma, Shionogi Inc., Spero Therapeutics, VenatoRx
  • Speaker’s Bureau: Merck & Co., Inc., Shionogi Inc.
Dr. Rodvold does not discuss off-label uses of any products.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in. Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from Adobe Flash Player version 10 or above to view multimedia content (If you do not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2020 Vemco MedEd. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.



Start Activity

By clicking on the activity icon below, I acknowledge that I have read the entire CME/CPE information.